アジア太平洋のてんかん治療薬市場：地域別分析 - 治療別、流通チャネル別、予測（～2030年）

アジア太平洋のてんかん治療薬の市場規模は、2022年に21億9,872万米ドルに達し、2022～2030年にかけてCAGR 4.6%で成長し、2030年には31億4,344万米ドルに達すると予測されています。

高齢者の増加がアジア太平洋のてんかん治療薬市場を活性化

てんかん治療薬市場は、今後数年間で多くの特許切れが予想されます。医療費削減のため、ジェネリック医薬品の普及が進むと思われます。これにより、他の市場プレーヤーにも新たなビジネスチャンスが生まれると思われます。以下は、今後数年で特許満了を迎える医薬品です。

会社名 特許権 有効期限 成分 治療法

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

アジア太平洋のてんかん治療薬の市場概要

アジア太平洋のてんかん治療薬市場は、中国、日本、インド、オーストラリア、韓国、その他のアジア太平洋に基づいて分析されます。世界保健機関（WHO）の報告書によると、てんかんは先進国よりも新興諸国の方が多く、有病率はそれぞれ6.1%と5.0%です。中国は世界で最も人口の多い国であり、神経疾患の患者が最も多い国です。中国疾病管理予防センターによると、中国における活動性てんかんの有病率は0.48～8.5％で、中国本土のてんかん患者数は約900万人で、その3分の2は小児です。~てんかん患者の約30%は、現在市販されているAEDでは発作をコントロールできないため、この疾患には大きなアンメットメディカルニーズがあります。

さらに、国内での医薬品承認が市場成長を後押ししています。例えば、Eisai Co., Ltd.は2021年8月、抗てんかん薬（AED）であるFycompaについて、中国国家医薬品監督管理局（National Medical Products Administration）から「部分てんかん発作の単剤療法」および「4歳以上のてんかん患者における部分てんかん発作の小児適応の併用療法／単剤療法」の2つの追加承認を取得しました。

アジア太平洋のてんかん治療薬市場の収益と2030年までの予測（金額）

アジア太平洋のてんかん治療薬市場セグメンテーション

アジア太平洋のてんかん治療薬市場は、治療、流通チャネル、国別にセグメンテーションされます。

治療に基づき、アジア太平洋のてんかん治療薬市場は、第一世代抗てんかん薬、第二世代抗てんかん薬、第三世代抗てんかん薬に分類されます。2022年には第3世代抗てんかん薬セグメントが最大のシェアを占めています。

流通チャネルでは、アジア太平洋のてんかん治療薬市場は病院薬局、小売薬局、その他に分類されます。病院薬局セグメントが2022年に最大のシェアを占めました。

国別に見ると、アジア太平洋のてんかん治療薬市場は、中国、日本、インド、オーストラリア、韓国、その他のアジア太平洋に区分されます。2022年のアジア太平洋てんかん治療薬市場は中国が支配的でした。

Abbott Laboratories、Alkem Laboratories Ltd、GSK Plc、Novartis AG、Pfizer Inc、Sanofi SA、Teva Pharmaceutical Industries Ltdは、アジア太平洋のてんかん治療薬市場で事業を展開している大手企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

• 主要な洞察

第3章 調査手法

• 調査範囲
• 2次調査
• 1次調査

第4章 てんかん治療薬の市場情勢

第5章 アジア太平洋のてんかん治療薬市場：主要産業力学

• 市場促進要因
  • てんかんの有病率の増加
  • 高齢者の増加
• 市場抑制要因
  • 治療製品の回収
• 市場機会
  • 複数のてんかん治療薬の特許切れ間近
• 今後の動向
  • 製品承認の増加
• 影響分析

第6章 てんかん治療薬市場：アジア太平洋の市場分析

• アジア太平洋のてんかん治療薬市場の収益、2022～2030年

第7章 アジア太平洋のてんかん治療薬市場：収益と予測（～2030年） - 治療別

• アジア太平洋のてんかん治療薬市場の収益、治療別（2022年・2030年（%））
• 第一世代抗てんかん薬
• 第二世代抗てんかん薬
• 第三世代抗てんかん薬

第8章 アジア太平洋のてんかん治療薬市場：収益と予測（～2030年） - 流通チャネル別

• アジア太平洋のてんかん治療薬市場の収益、流通チャネル別（2022年・2030年（%））
• 病院薬局
• 小売薬局店舗
• その他

第9章 アジア太平洋のてんかん治療薬市場：収益と予測（～2030年） - 国別分析

第10章 てんかん治療薬市場 - 産業情勢

• てんかん治療薬市場における成長戦略
• 無機的成長戦略
• 有機的成長戦略

第11章 企業プロファイル

• Novartis AG
• Pfizer Inc
• GSK Plc
• Abbott Laboratories
• Sanofi SA
• Teva Pharmaceutical Industries Ltd
• Alkem Laboratories Ltd

第12章 付録

List Of Tables

• Table 1. Asia Pacific Epilepsy Drugs Market Segmentation
• Table 2. China: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 3. China: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 4. Japan: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 5. Japan: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 6. India: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 7. India: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 8. Australia: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 9. Australia: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 10. South Korea: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 11. South Korea: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 12. Rest of Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 13. Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 14. Recent Inorganic Growth Strategies in the Epilepsy Drugs Market
• Table 15. Recent Organic Growth Strategies in the Asia Pacific Epilepsy Drugs Market
• Table 16. Glossary of Terms, Asia Pacific Epilepsy Drugs Market

List Of Figures

• Figure 1. Asia Pacific Epilepsy Drugs Market Segmentation, By Country
• Figure 2. Asia Pacific Epilepsy Drugs Market: Key Industry Dynamics
• Figure 3. Asia Pacific Epilepsy Drugs Market: Impact Analysis of Drivers and Restraints
• Figure 4. Asia Pacific Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030
• Figure 5. Asia Pacific Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
• Figure 6. First Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 7. Second Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 8. Third Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 9. Asia Pacific Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
• Figure 10. Hospital Pharmacy: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 11. Retail Pharmacy Stores: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 12. Others: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 13. Asia Pacific Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
• Figure 14. Asia Pacific Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
• Figure 15. China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 16. Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 17. India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 18. Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 19. South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 20. Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 21. Growth Strategies in the Epilepsy Drugs Market

The Asia Pacific epilepsy drugs market was valued at US$ 2,198.72 million in 2022 and is expected to reach US$ 3,143.44 million by 2030; it is estimated to grow at a CAGR of 4.6% from 2022 to 2030.

Increasing Number of Elderly People Fuels the Asia Pacific Epilepsy Drugs Market

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

Asia Pacific Epilepsy Drugs Market Overview

The Asia Pacific epilepsy drugs market is analysed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively. China is the most populated country in the world and the one with the most patients with neurological disorders. According to the Centers of Disease Control and Prevention, in China, the prevalence rate of active epilepsy is 0.48% to 8.5%; there are approximately 9 million people with epilepsy in Mainland China, two-thirds of whom are children. ~30% of patients with epilepsy are not capable of controlling their seizures with the AEDs that are currently available in the market; thus, this disease has significant unmet medical needs.

Moreover, the drug approvals in the country are propelling the market growth. For instance, in August 2021, Eisai Co., Ltd. obtained two additional approvals of the antiepileptic drug (AED) Fycompa, as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for a pediatric indication for partial onset seizures in patients with epilepsy four years of age and older" in China from the National Medical Products Administration.

Asia Pacific Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Drugs Market Segmentation

The Asia Pacific epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the Asia Pacific epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the Asia Pacific epilepsy drugs market is segmented China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific epilepsy drugs market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Epilepsy Drugs Market Landscape

• 4.1 Overview

5. Asia Pacific Epilepsy Drugs Market - Key Industry Dynamics

• 5.1 Market Drivers
  • 5.1.1 Growing Prevalence of Epilepsy
  • 5.1.2 Increasing Number of Elderly People
• 5.2 Market Restraints
  • 5.2.1 Recall of Therapeutic Products
• 5.3 Market Opportunities
  • 5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
• 5.4 Future Trends
  • 5.4.1 Increasing Product Approvals
• 5.5 Impact Analysis

6. Epilepsy Drugs Market - Asia Pacific Market Analysis

• 6.1 Overview
• 6.2 Asia Pacific Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030

7. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment

• 7.1 Overview
• 7.2 Asia Pacific Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
• 7.3 First Generation Antiepileptics
  • 7.3.1 Overview
  • 7.3.2 First Generation Antiepileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Second Generation Anti-epileptics
  • 7.4.1 Overview
  • 7.4.2 Second Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Third Generation Anti-epileptics
  • 7.5.1 Overview
  • 7.5.2 Third Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel

• 8.1 Overview
• 8.2 Asia Pacific Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
• 8.3 Hospital Pharmacy
  • 8.3.1 Overview
  • 8.3.2 Hospital Pharmacy: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Retail Pharmacy Stores
  • 8.4.1 Overview
  • 8.4.2 Retail Pharmacy Stores: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Others
  • 8.5.1 Overview
  • 8.5.2 Others: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - Country Analysis

• 9.1 Asia Pacific Epilepsy Drugs Market, by Key Country- Revenue (2022) (US$ Million)
  • 9.1.1 Asia Pacific Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
    • 9.1.1.1 China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.1.1 Overview
      • 9.1.1.1.2 China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.1.3 China: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.1.4 China: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.2 Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.2.1 Overview
      • 9.1.1.2.2 Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.2.3 Japan: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.2.4 Japan: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.3 India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.3.1 Overview
      • 9.1.1.3.2 India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.3.3 India: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.3.4 India: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.4 Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.4.1 Overview
      • 9.1.1.4.2 Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.4.3 Australia: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.4.4 Australia: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.5 South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.5.1 Overview
      • 9.1.1.5.2 South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.5.3 South Korea: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.5.4 South Korea: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.6 Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.6.1 Overview
      • 9.1.1.6.2 Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.6.3 Rest of Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.6.4 Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Epilepsy Drugs Market-Industry Landscape

• 10.1 Overview
• 10.2 Growth Strategies in the Epilepsy Drugs Market
• 10.3 Inorganic Growth Strategies
  • 10.3.1 Overview
• 10.4 Organic Growth Strategies
  • 10.4.1 Overview

11. Company Profiles

• 11.1 Novartis AG
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 Pfizer Inc
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 GSK Plc
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 Abbott Laboratories
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 Sanofi SA
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 Teva Pharmaceutical Industries Ltd
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Services
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 Alkem Laboratories Ltd
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments

12. Appendix

• 12.1 About Us
• 12.2 Glossary of Terms